purine-based covalent CDK12 inhibitors (AstraZeneca/Pharmaron)

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug Namepurine-based covalent CDK12 inhibitors (AstraZeneca/Pharmaron)
Drug Alias NameCDK12 inhibitors (AstraZeneca/Pharmaron)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 12 inhibitors
TargetsCyclin-dependent kinase 12
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A